Getinge AB (publ) (STO:GETI.B)

Revenue Breakdown

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Acute Care Therapies Revenue	19.12B	17.95B	16.53B
Acute Care Therapies Revenue Growth	6.53%	8.58%	8.14%
Life Science Revenue	4.66B	4.55B	4.33B
Life Science Revenue Growth	2.42%	5.25%	7.43%
Surgical Workflows Revenue	12.07B	12.26B	10.97B
Surgical Workflows Revenue Growth	-1.53%	11.70%	22.19%

Revenue by Geography

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Americas Revenue	16.13B	15.52B	13.15B
Americas Revenue Growth	3.96%	18.03%	14.64%
APAC Revenue	7.30B	7.06B	6.94B
APAC Revenue Growth	3.38%	1.70%	3.70%
EMEA Revenue	12.42B	12.18B	11.74B
EMEA Revenue Growth	1.99%	3.77%	15.88%

Revenue Breakdown 2

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Capital Goods Revenue	12.47B	12.42B	12.47B
Capital Goods Revenue Growth	0.42%	-0.43%	12.37%
Product Sales Recurring Revenue	16.48B	15.59B	12.96B
Product Sales Recurring Revenue Growth	5.74%	20.26%	11.19%
Service Assignments Incl. Spare Parts Recurring Revenue	6.90B	6.75B	6.39B
Service Assignments Incl. Spare Parts Recurring Revenue Growth	2.22%	5.62%	15.53%
Total Recurring Revenue	23.38B	22.34B	19.35B
Total Recurring Revenue Growth	4.68%	15.42%	12.58%

Gross Profit

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Acute Care Therapies Gross Profit	10.38B	9.62B	9.03B
Acute Care Therapies Gross Profit Growth	7.92%	6.49%	4.99%
Life Science Gross Profit	1.71B	1.70B	1.43B
Life Science Gross Profit Growth	0.53%	18.52%	-2.72%
Surgical Workflows Gross Profit	4.82B	4.84B	4.04B
Surgical Workflows Gross Profit Growth	-0.37%	20.00%	20.84%

EBIT

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Acute Care Therapies Operating Profit	2.50B	2.07B	3.22B
Acute Care Therapies Operating Profit Growth	21.26%	-35.77%	11.28%
Life Science Operating Profit	530.00M	526.00M	395.00M
Life Science Operating Profit Growth	0.76%	33.16%	-34.17%
Surgical Workflows Operating Profit	937.00M	703.00M	675.00M
Surgical Workflows Operating Profit Growth	33.29%	4.15%	40.63%
Group Functions and Other Items Operating Profit	-469.00M	-440.00M	-549.00M

Adjusted EBITDA

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Acute Care Therapies Adjusted EBITA	3.93B	3.55B	3.12B
Acute Care Therapies Adjusted EBITA Growth	10.61%	14.02%	-8.38%
Life Science Revenue Adjusted EBITA	610.00M	608.00M	430.00M
Life Science Revenue Adjusted EBITA Growth	0.33%	41.39%	-33.85%
Surgical Workflows Adjusted EBITA	1.12B	1.09B	721.00M
Surgical Workflows Adjusted EBITA Growth	3.03%	51.18%	31.33%
Group Functions and Other Items Adjusted EBITA	-451.00M	-383.00M	-381.00M

Key Performance Indicators

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Acute Care Therapies - Order Intake	18.60B	17.72B	16.38B
Acute Care Therapies - Order Intake Growth	4.99%	8.21%	1.66%
Life Science - Order Intake	4.48B	4.60B	4.15B
Life Science - Order Intake Growth	-2.72%	10.92%	5.49%
Surgical Workflows - Order Intake	11.66B	11.91B	10.37B
Surgical Workflows - Order Intake Growth	-2.10%	14.86%	8.24%
Total Order Intake	34.74B	34.23B	30.89B
Total Order Intake Growth	1.49%	10.80%	4.30%
Order Intake - Organic Growth	-	6.30%	-1.60%
Acute Care Therapies Net Sales - Organic Growth	-	8.20%	3.90%
Life Science Net Sales - Organic Growth	-	-1.90%	-0.90%
Surgical Workflows Net Sales - Organic Growth	-	2.60%	13.90%
Total Net Sales - Organic Growth	-	4.90%	6.40%

Updated Sep 30, 2025. Data Source: Fiscal.ai.